Abstract: Methods, apparatuses and systems for providing gas detecting apparatuses (e.g., electrochemical detectors) are disclosed herein. An example gas detecting apparatus may comprise a sensing component comprising: a first sensing electrode configured to generate a first concentration level indication associated with a first portion of a sample gaseous substance disposed within the sensing component; and a second sensing electrode operatively coupled to a filtering element that is configured to absorb at least one substance from the sample gaseous substance, wherein the second sensing electrode is configured to generate a second concentration level indication associated with a second portion of the sample gaseous substance.

Abstract: The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.

Abstract: Certain aspects of the present disclosure provide techniques for channel state information (CSI) processing occupation determination that can be used even in multiple transmission reception point (mTRP) scenarios. A method that may be performed by a user equipment (UE) includes receiving a channel state information (CSI) reporting configuration configuring the UE with a plurality of CSI reference signal (CSI-RS) resources for channel measurement (CMRs). The method includes determining a number of occupied CSI processing units, a number of occupied active CSI resources, and/or a number of occupied active CSI-RS ports based on an actual number of CSI measurements. The method includes performing CSI measurement based on the determination.

Abstract: A docker image is received. The docker image is for a container. The container contains files that allow for virtualization of applications that run within the container. The docker image is parsed to identify layer files in the docker image. Installed software components (e.g., installed files) and/or hardware components in the layer files are identified. Software application index calls are made to generate information that identifies relationships between the installed software components and/or hardware components. The relationships between the installed software components and/or hardware components are then displayed to a user.

Abstract: A user equipment (UE) includes: a transceiver configured to receive positioning signals; a memory; and a processor, communicatively coupled to the transceiver and the memory, configured to: send, via the transceiver to a network entity, a capability indication that includes a first positioning-method indication indicating that the processor supports simultaneous processing of a first combination of positioning methods; and simultaneously process one or more first positioning signals in accordance with the first combination of positioning methods to determine first position information for the UE.

Abstract: The present disclosure relates to systems and methods for immune therapy. For example, a method can be used to enhance proliferation of chimeric antigen receptor (CAR) T cells in a patient, The method comprises administering to the patient an effective amount of a pharmaceutical composition comprising lymphocyte activation agents and one or more recombinant viral particles comprising a polynucleotide encoding a CAR, wherein the proliferation of CAR T cells in the patient is greater as compared to a patient administered with the one or more recombinant viral particles but without the lymphocyte activation agents.

Abstract: Embodiments described herein relate to compositions including genetically modified CAR cells and uses thereof for treating cancer. Some embodiments of the present disclosure relate to compositions and methods for T cell response enhancement and/or CAR cell preparation. For example, a method may include obtaining cells comprising a CAR and culturing the cells in the presence of an agent that is recognized by the extracellular domain of the CAR.

Abstract: Apparatus and associated methods relate to a one-piece structure for a solid electrolyte chemical sensor (SECS) having a first surface defining a cavity (210, 305, 415) designed to receive a substrate (215, 350, 410) that retains a solid electrolyte (365, 440), an internal water impermeable coating (425) on at least a portion of the first surface, a second surface that is substantially coplanar with an adjacent peripheral edge of a top surface of the substrate (215, 350, 410) when the substrate (215, 350, 410) is received in the cavity (210, 305, 415), and a plurality of electrical contacts (335, 340, 345, 450a-450b) disposed on the second surface adapted to electrically couple with the electrodes (435a-435c) on the substrate (215, 350, 410) when the substrate (215, 350, 410) is received in the cavity (210, 305, 415) and electrical paths are provided between respective electrical contacts (335, 340, 345, 450a-450b) and electrodes (435a-435c).

Abstract: A method is implemented in a digital unit connected with a plurality of distributed antennas including a first antenna, a second antenna and a third antenna. The method comprises: causing transmitting a first signal from the first antenna, a second signal from the second antenna, and a third signal from the third antenna in a same frequency resource; obtaining a receiver and transmitter side loop-back phase difference between the first antenna and the second antenna based on the first signal received at the third antenna, the second signal received at the third antenna, the third signal received at the first antenna, and the third signal received at the second antenna; and obtaining estimations of a time delay difference and an initial phase difference between the first and second antennas based on the obtained loop-back phase difference.

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Abstract: Compositions and methods for enhancing T cell response which increases the efficacy of CAR T cell therapy for treating cancer are described. Embodiments include a modified cell comprising an isolated nucleic acid comprising a first nucleic acid and a second nucleic acid, the first nucleic acid encoding a chimeric antigen receptor (CAR), the second nucleic acid encoding a therapeutic agent comprising at least one of IFN-?, IL-2, IL-6, IL-7, IL-15, IL-17, and IL-23. The modified cell expresses and secretes the therapeutic agent.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may indicate, to a base station, a capability of the UE to use a channel measurement resource for both a joint transmission hypothesis and a single transmission hypothesis. The UE may receive, based on indicating the capability of the UE, a configuration message indicating a first channel measurement resource that is associated with a first transmission configuration indicator state and that is configured for a first joint transmission hypothesis. The UE may obtain a channel measurement for both the first joint transmission hypothesis and a first single transmission hypothesis using the first channel measurement resource based on the configuration message.

Abstract: This application provides a method and apparatus for configuring a quality of service policy for a service, and a computing device, and belongs to the field of network communications technologies. The method includes: obtaining a first data flow forwarded by a virtual switch; determining service information of the first data flow, where the service information includes a service type of the first data flow and an access path of the first data flow; determining, based on the service information of the first data flow, a quality of service QoS policy matching the first data flow; and configuring devices on the access path based on the matched QoS policy. According to this application, efficiency of configuring a quality of service policy for a service can be improved.

Abstract: A method is implemented in a digital unit connected with a plurality of distributed antennas including a first antenna, a second antenna and a third antenna. The method comprises: causing transmitting a first signal from the first antenna, a second signal from the second antenna, and a third signal from the third antenna in a same frequency resource; obtaining a receiver and transmitter side loop-back phase difference between the first antenna and the second antenna based on the first signal received at the third antenna, the second signal received at the third antenna, the third signal received at the first antenna, and the third signal received at the second antenna; and obtaining estimations of a time delay difference and an initial phase difference between the first and second antennas based on the obtained loop-back phase difference.

Abstract: In one embodiment, a method includes receiving a pair of stereo images having a resolution lower than a target resolution, generating an initial first feature map for a first image of the pair based on first channels associated with the first image and generating an initial second feature map for a second image of the pair based on second channels associated with the second image, generating a first feature map based on combining the first channels with the initial first feature map, generating a second feature map based on combining the second channels with the initial second feature map, up-sampling the first feature map and the second feature map to the target resolution, warping the up-sampled second feature map, and generating a reconstructed image corresponding to the first image having the target resolution based on the up-sampled first feature map and the up-sampled and warped second feature map.

Abstract: Certain aspects of the present disclosure provide techniques for determining channel state information (CSI) reference signal (CSI-RS) resources and ports occupation for finer precoding matrix indication (PMI) granularity.

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.

Abstract: A user equipment (UE) may utilize frequency domain (FD) compression for reporting channel state information (CSI) including a precoding matrix indicator (PMI). The UE may receive a CSI configuration specifying a first set of configured FD units to be reported. The UE may determine a first number of FD units based on the first set of configured FD units. The UE may select a second number of FD units that is greater than or equal to the first number of FD units. The UE may calculate, for one or more layers, a PMI for a second set of FD units including a number of FD units equal to the second number of FD units. The UE may allocate, according to a mapping rule, a number of PMIs for the first set of FD units to a subset of the PMIs for the second set of FD units.

Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.